AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 33 min read$PFE

Pfizer earnings take a tumble as revenue slips in third quarter

Pfizer reported Q3 earnings of $3.242B ($0.56/share), down from $3.541B ($0.62/share) last year. Adjusted earnings were $4.985B ($0.87/share). Revenue fell 0.4% to $16.583B. The company appointed Cecile Guegan as CFO. Shares rose 0.29% premarket.

Original reporting
finance.yahoo.com
Published Nov 3, 2026, 1:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 2:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Pfizer earnings take a tumble as revenue slips in third quarter — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$PFEBearishMed
01

Why it matters

The core trading driver is the year-over-year decline in revenue and EPS; the CFO appointment is a secondary governance catalyst that may reduce uncertainty about financial leadership continuity.

02

Market read

This is a company-specific earnings print with concrete year-over-year revenue and EPS changes, plus an executive transition that can affect investor confidence in financial oversight.

03

What to watch

No guidance, segment performance, or margin details are provided here, so the market reaction could hinge on information not included in this excerpt.

Relevance 8/10Novelty 7/10Timing: after-hours/next-session positioning following the Q3 earnings release

Background

The piece reports Pfizer’s Q3 earnings results and a CFO succession decision, with premarket share performance noted.

Company-level read

Ticker impact

$PFEBearishHigh confidence
Context

Pfizer reported Q3 revenue down 0.4% to $16.583B and EPS $0.56, alongside a CFO appointment effective Nov. 1.

Expected impact

Shares may face pressure as investors weigh the year-over-year revenue and EPS decline, with limited support from the CFO transition news.

Evidence & confidence

The article provides the company’s own quarterly revenue and EPS comparisons versus the prior year, which typically drive immediate repricing; the CFO appointment is supportive but not a direct earnings catalyst.

Market effects

Sector

Large pharma peers may see mild read-through on demand and pricing trends if investors interpret the revenue decline as sector-relevant softness.

Regional

Primarily US large-cap pharma sentiment; limited direct regional spillover beyond healthcare equities.

Global

Could modestly influence global pharma risk appetite, but the article contains no guidance or macro/regulatory shocks.

Counterpoint

What could challenge this read

The revenue decline is small (-0.4%) and the article highlights adjusted earnings; investors may focus on underlying profitability rather than headline revenue/EPS.

Key entities

  • company
    Pfizer

    US pharmaceutical company reporting Q3 earnings and appointing a new CFO effective Nov. 1.

  • person
    Cecile Guegan

    Appointed Pfizer CFO and executive vice president, effective Nov. 1, after serving as interim CFO.

Read at source← All news

StoryPfizer posts Q3 beat, raises FY‑26 outlook and names new CFO

Also covered by

3 outlets

Related articles

NOV 3
$PFEHighAI 9/10

Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive Q3 beat

Pfizer raised its 2026 forecasts after strong Q3 results, driven by cancer drugs and Eliquis. Revenue was $16.58B, beating estimates. The company targets $62B-$64B in annual sales, up from prior forecasts. Adjusted EPS is expected to be $2.95-$3.05. Pfizer aims for $9.7B in cost savings by 2029. CEO Albert Bourla cited strong performance and confidence in growth prospects.

ctvnews.ca2 min
NOV 3
$PFEHighAI 9/10

Pfizer Q3 2026 earnings beat estimates, full-year outlook raised

Pfizer reported Q3 2026 revenue of $16.58B, down slightly YoY but up 7% excluding Comirnaty and Paxlovid. Full-year revenue guidance raised to $62B-$64B, with adjusted EPS of $2.95-$3.05. The outlook includes a $650M charge from an agreement with Innovent Biologics. Analysts expected lower revenue and EPS.

qz.com2 min
NOV 3
$PFEHighAI 9/10

Pfizer raises sales forecast after Q3 2026 earnings beat

Pfizer raised its 2023 revenue forecast to $62.0B-$64.0B, up from $60.5B-$62.5B, and adjusted EPS guidance to $2.95-$3.05. Q3 revenue was $16.6B, flat YoY, with adjusted EPS at 87 cents. Revenue from launched and acquired products rose 32%, while Paxlovid and Comirnaty revenue declined.

qz.com2 min